Envista (NYSE:NVST) Given New $19.00 Price Target at JPMorgan Chase & Co.

Envista (NYSE:NVST) had its target price cut by equities researchers at JPMorgan Chase & Co. from $20.00 to $19.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price objective points to a potential upside of 5.97% from the company’s previous close.

A number of other research firms also recently issued reports on NVST. Jefferies Financial Group lifted their price objective on Envista from $20.00 to $22.00 and gave the stock a “hold” rating in a research note on Thursday, January 23rd. Morgan Stanley lowered their price objective on shares of Envista from $20.00 to $19.00 and set an “equal weight” rating for the company in a research report on Thursday. Mizuho initiated coverage on shares of Envista in a report on Wednesday, December 4th. They set an “underperform” rating and a $20.00 target price on the stock. Wells Fargo & Company lifted their price target on Envista from $20.00 to $21.00 and gave the company an “equal weight” rating in a report on Thursday, February 6th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Envista in a research report on Thursday. Two analysts have rated the stock with a sell rating, nine have given a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $20.38.

Envista Price Performance

Shares of NVST traded down $0.31 during trading hours on Thursday, reaching $17.93. 636,254 shares of the stock traded hands, compared to its average volume of 2,247,984. The company has a market cap of $3.09 billion, a P/E ratio of -2.76, a price-to-earnings-growth ratio of 1.27 and a beta of 1.33. The company has a current ratio of 2.04, a quick ratio of 1.76 and a debt-to-equity ratio of 0.44. The company’s 50-day moving average price is $20.27 and its two-hundred day moving average price is $19.69. Envista has a 52-week low of $15.15 and a 52-week high of $23.00.

Envista (NYSE:NVST) last issued its earnings results on Wednesday, February 5th. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. On average, analysts anticipate that Envista will post 1 earnings per share for the current year.

Institutional Trading of Envista

Hedge funds and other institutional investors have recently made changes to their positions in the business. Huntington National Bank grew its position in Envista by 97.8% during the 3rd quarter. Huntington National Bank now owns 1,919 shares of the company’s stock worth $38,000 after purchasing an additional 949 shares during the period. Venturi Wealth Management LLC raised its position in Envista by 528.4% during the fourth quarter. Venturi Wealth Management LLC now owns 1,948 shares of the company’s stock valued at $38,000 after acquiring an additional 1,638 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Envista by 30.5% in the fourth quarter. GAMMA Investing LLC now owns 2,304 shares of the company’s stock valued at $44,000 after acquiring an additional 538 shares during the period. Thurston Springer Miller Herd & Titak Inc. purchased a new position in shares of Envista during the 4th quarter valued at approximately $53,000. Finally, Mitsubishi UFJ Trust & Banking Corp purchased a new stake in Envista during the fourth quarter worth $86,000.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.